{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:40:10Z","timestamp":1781660410233,"version":"3.54.5"},"reference-count":41,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Antisecretory drugs are frequently used in the treatment of pediatric gastrointestinal disorders. This study was aimed to assess the prescribing patterns and the safety of ranitidine and proton pump inhibitors (PPIs) in a cohort of Italian pediatric patients. Children aged &gt;1 month to &lt;16 years that were admitted to our Pediatric Clinic between 2016 and 2018 were enrolled in this retrospective observational study. All data were obtained from medical records and a parent telephone questionnaire. The exclusion criteria included the use of antisecretory therapy at hospital admission, failure to collect the relevant clinical data, and failure to administer the questionnaire. This study included 461 subjects, who were divided into four age groups: &lt;2 years, 2\u20135 years, 6\u201311 years, and \u226512 years. Ranitidine was prescribed in 396 (85.9%) patients, mainly for the acute treatment of gastrointestinal symptoms, and a PPI was given to 65 (14.1%) children to treat gastroesophageal reflux disease, gastritis\/ulcer, or for gastroprotection. During the study period, the percentage of patients treated with ranitidine progressively increased, except in the 2\u20135-year age group. We observed eighty-seven adverse drug reactions (ADRs), 61 of which occurred in the ranitidine group and 26 in the PPI group. The most common ADR was constipation (n = 35), which occurred more frequently in children treated with PPIs and in the 6\u201311-year age group. Ranitidine was the most used antisecretory drug in all the age groups, especially for acute treatment. Conversely, PPIs were the drugs of choice for prolonged treatments. Further research should be focused on developing an effective and safer alternative to ranitidine.<\/jats:p>","DOI":"10.3390\/jcm12010368","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T02:33:21Z","timestamp":1672713201000},"page":"368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Use of Gastric Antisecretory Drugs in Hospitalized Pediatric Patients"],"prefix":"10.3390","volume":"12","author":[{"given":"Cristian","family":"Locci","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cuzzolin","sequence":"additional","affiliation":[{"name":"Department of Diagnostics & Public Health, Section of Pharmacology, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-528X","authenticated-orcid":false,"given":"Gianluca","family":"Cheri","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-9367","authenticated-orcid":false,"given":"Laura","family":"Saderi","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4474","authenticated-orcid":false,"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-7904","authenticated-orcid":false,"given":"Roberto","family":"Antonucci","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13052-016-0272-5","article-title":"Pharmacological interventions on early functional gastrointestinal disorders","volume":"42","author":"Salvatore","year":"2016","journal-title":"Ital. J. Pediatr."},{"key":"ref_2","unstructured":"National Institute for Health and Care Excellence (2022, April 20). Gastro-Oesophageal Reflux Disease in Children and Young People: Diagnosis and Management. Available online: https:\/\/www.nice.org.uk\/guidance\/ng1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/aas.12099","article-title":"Stress ulcer prophylaxis in the intensive care unit: Is it indicated? A topical systematic review","volume":"57","author":"Krag","year":"2013","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1684","DOI":"10.1542\/peds.2013-0421","article-title":"American Academy of Pediatrics Section on Gastroenterology, Hepatology and Nutrition. Gastroesophageal reflux: Management guidance for the paediatrician","volume":"131","author":"Lightdale","year":"2013","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1572-0241.2000.t01-1-01808.x","article-title":"Fatal hepatitis associated with ranitidine","volume":"95","author":"Ribeiro","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.308.6927.503","article-title":"Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs","volume":"308","author":"Jick","year":"1994","journal-title":"BMJ"},{"key":"ref_7","unstructured":"Food and Drug Administration (2022, May 22). FDA Requests Removal of All Ranitidine Products (Zantac) from the Market, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requests-removal-all-ranitidine-products-zantac-market."},{"key":"ref_8","unstructured":"Agenzia Italiana del Farmaco (2022, May 20). Comunicazione AIFA Sui Farmaci Contenenti Ranitidina, Available online: https:\/\/www.aifa.gov.it\/-\/comunicazione-aifa-sui-farmaci-contenenti-ranitidina."},{"key":"ref_9","unstructured":"European Medicines Agency (2022, May 22). EMA Confirms Recommendation to Suspend All Ranitidine Medicines in the EU, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/ranitidine-containing-medicinal-products."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"839972","DOI":"10.3389\/fphar.2022.839972","article-title":"A narrative review on efficacy and safety of proton pump inhibitors in children","volume":"13","author":"Dipasquale","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MPG.0000000000001596","article-title":"National study of off-label proton pump inhibitor use among New Zealand infants in the first year of life (2005\u20132012)","volume":"65","author":"Blank","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_12","first-page":"660","article-title":"Acid suppressants for managing gastro-oesophageal reflux disease in infants: A national survey","volume":"103","author":"Bell","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"212591","DOI":"10.7573\/dic.212591","article-title":"Gastroesophageal reflux in children: An updated review","volume":"8","author":"Leung","year":"2019","journal-title":"Drugs Context"},{"key":"ref_14","first-page":"1957","article-title":"Prescription of acid inhibitors in infants: An addiction hard to break","volume":"179","author":"Levy","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rybak, A., Pesce, M., Thapar, N., and Borrelli, O. (2017). Gastro-esophageal reflux in children. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081671"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1067\/S0022-3476(03)00207-5","article-title":"Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux","volume":"143","author":"Moore","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/phar.1299","article-title":"Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease","volume":"33","author":"Tjon","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/archdischild-2017-314026","article-title":"Toxicity of long-term use of proton pump inhibitors in children","volume":"103","author":"Ito","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bcp.12619","article-title":"Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: A 10 years literature review","volume":"80","author":"Cohen","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MPG.0000000000001467","article-title":"Esomeprazole FDA approval in children with GERD: Exposure-matching and exposure-response","volume":"65","author":"Earp","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: Definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MPG.0b013e3182a3b04e","article-title":"Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: Analysis of the national database (1997\u20132009)","volume":"58","author":"Christiaens","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e20182625","DOI":"10.1542\/peds.2018-2625","article-title":"Early acid suppression therapy exposure and fracture in young children","volume":"144","author":"Malchodi","year":"2019","journal-title":"Pediatrics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MOP.0b013e328363ed4e","article-title":"Off-label use of medicine in pediatrics: Focus on gastrointestinal diseases","volume":"25","author":"Karesh","year":"2013","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1542\/peds.2010-2719","article-title":"Efficacy of Proton-Pump Inhibitors in Children with Gastroesophageal Reflux Disease: A Systematic Review","volume":"127","author":"Smits","year":"2011","journal-title":"Pediatrics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MPG.0000000000001952","article-title":"Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis","volume":"67","author":"Cilleruelo","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1080\/03007995.2017.1354830","article-title":"Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: An observational cohort study","volume":"33","author":"Johansson","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MPG.0000000000001889","article-title":"Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)","volume":"66","author":"Rosen","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_29","first-page":"705","article-title":"Diagnosis and Treatment of Gastroesophageal Reflux in Infants and Children","volume":"92","author":"Baird","year":"2015","journal-title":"Am. Fam. Physician"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jpeds.2008.09.054","article-title":"Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of Gastroesophageal Reflux Disease","volume":"154","author":"Orenstein","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/MPG.0000000000001401","article-title":"ESPGHAN-NASPGHAN Guidelines for the Evaluation and Treatment of Gastrointestinal and Nutritional Complications in Children with Esophageal Atresia-Tracheoesophageal Fistula","volume":"63","author":"Kirshnan","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MPG.0b013e3182a80be1","article-title":"Management guidelines of eosinophilic esophagitis in childhood","volume":"58","author":"Papadopoulou","year":"2014","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fmed.2018.00247","article-title":"Eosinophilic Esophagitis: Review and Update","volume":"5","author":"Alvarado","year":"2018","journal-title":"Front. Med."},{"key":"ref_34","unstructured":"Hughes, H.K., and Kahl, L.K. (2017). The Johns Hopkins Hospital: The Harriet Lane Handbook, Elsevier. [21st ed.]."},{"key":"ref_35","unstructured":"Brunton, L., and Hilal-Dandan, R. (2018). Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, McGraw-Hill. [13th ed.]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1542\/pir.24.1.12","article-title":"What\u2019s New: Proton Pump Inhibitors and Pediatrics","volume":"24","author":"Patel","year":"2003","journal-title":"Pediatr. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00003088-200544050-00001","article-title":"Pharmacokinetics of Proton Pump Inhibitors in Children","volume":"44","author":"Litalien","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_38","unstructured":"European Medicines Agency (2022, May 20). Nitrosamine Impurities, Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/nitrosamine-impurities."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jama.2021.10043","article-title":"Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation","volume":"326","author":"White","year":"2021","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cts.12753","article-title":"Medicine and Media: The Ranitidine Debate","volume":"13","author":"Wagner","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2165\/00003495-198937060-00003","article-title":"Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases","volume":"37","author":"Grant","year":"1989","journal-title":"Drugs"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:56:55Z","timestamp":1760119015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010368"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010368","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}